{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"4.0","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. Progression is defined using modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions or RECIST 1.1 if mRECIST cannot be used.","dispersionType":"95% Confidence Interval","groups":[{"description":"Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.","id":"OG000","title":"Alisertib"}],"paramType":"MEDIAN","populationDescription":"1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.","reportingStatus":"POSTED","timeFrame":"From treatment start to death/progression or last follow-up, whichever come first assessed up to 25 months.","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}